Author Nogami, Naoyuki| Hotta, Katsuyuki| Kuyama, Shoichi| Kiura, Katsuyuki| Takigawa, Nagio| Chikamori, Kenichi| Shibayama, Takuo| Kishino, Daizo| Hosokawa, Shinobu| Tamaoki, Akihiko| Harita, Shingo| Tabata, Masahiro| Ueoka, Hiroshi| Shinkai, Tetsu| Tanimoto, Mitsune|
Published Date 2011-10
Publication Title Lung Cancer
Volume volume74
Issue issue1
Content Type Journal Article
Author Ninomiya, Takashi| Takigawa, Nagio| Ichihara, Eiki| Ochi, Nobuaki| Murakami, Toshi| Honda, Yoshihiro| Kubo, Toshio| Minami, Daisuke| Kudo, Kenichiro| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2013-05
Publication Title Molecular Cancer Therapeutics
Volume volume12
Issue issue5
Content Type Journal Article
JaLCDOI 10.18926/AMO/54603
FullText URL 70_5_409.pdf
Author Maeda, Yoshinobu| Nishimori, Hisakazu| Inamoto, Yoshihiro| Nakamae, Hirohisa| Sawa, Masashi| Mori, Yasuo| Ohashi, Kazuteru| Fujiwara, Shin-ichiro| Tanimoto, Mitsune|
Abstract Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.
Keywords Am80 tamibarotene retinoid chronic GVHD steroid-refractory GVHD
Amo Type Clinical Study Protocols
Published Date 2016-10
Publication Title Acta Medica Okayama
Volume volume70
Issue issue5
Publisher Okayama University Medical School
Start Page 409
End Page 412
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27777437
Web of Science KeyUT 000388098700014
Author Soga, Yoshihiko| Maeda, Yoshinobu| Tanimoto, Mitsune| Ebinuma, Takayuki| Maeda, Hiroshi| Takashiba, Shogo|
Published Date 2013-02
Publication Title Supportive Care in Cancer
Volume volume21
Issue issue2
Content Type Journal Article
Author Sugiura, Yuko| Soga, Yoshihiko| Tanimoto, Ichiro| Kokeguchi, Susumu| Nishide, Sachiko| Kono, Kotoe| Takahashi, Kanayo| Fujii, Nobuharu| Ishimaru, Fumihiko| Tanimoto, Mitsune| Yamabe, Kokoro| Tsutani, Soichiro| Nishimura, Fusanori| Takashiba, Shogo|
Published Date 2008-04
Publication Title Supportive Care in Cancer
Volume volume16
Issue issue4
Content Type Journal Article
Author Soga, Yoshihiko| Maeda, Yoshinobu| Ishimaru, Fumihiko| Tanimoto, Mitsune| Maeda, Hiroshi| Nishimura, Fusanori| Takashiba, Shogo|
Published Date 2011-07
Publication Title Supportive Care in Cancer
Volume volume19
Issue issue7
Content Type Journal Article
Author Takata, Shingo| Mifune, Takashi| Mitsunobu, Fumihiro| Okamoto, Makoto| Nishida, Norikazu| Tsugeno, Hirofumi| Ashida, Kozo| Hosaki, Yasuhiro| Yokoi, Tadashi| Tanizaki, Yoshiro| Niiya, Kenji| Tanimoto, Mitsune|
Published Date 2003-02-01
Publication Title 岡大三朝医療センター研究報告
Volume volume73
Content Type Departmental Bulletin Paper
JaLCDOI 10.18926/AMO/31706
FullText URL fulltext.pdf
Author Shibakura, Misako| Niiya, Kenji| Kiguchi, Toru| Nakata, Yasunari| Tanimoto, Mitsune|
Abstract <p>We previously reported that anthracyclines, which could generate reactive oxygen species (ROS), could induce the urokinase-type plasminogen activator (uPA) gene expression in human RC-K8 malignant lymphoma cells and in H69 small cell lung cancer (SCLC) cells. In screening other uPA-inducible anti-cancer agents, we found that camptothecin (CPT) and its derivative, SN38, could induce uPA in RC-K8 and H69 cells. CPT and SN38, which are also used for the treatment of lymphoma and SCLC, significantly increased the uPA accumulation in the conditioned media of both cells in a dose-dependent manner. The maximum induction of uPA mRNA levels was observed 24 h after stimulation. Pretreatment with pyrrolidine dithiocarbamate (PDTC), an anti-oxidant, inhibited the CPT-induced uPA mRNA expression. Thus, CPT induces uPA through gene expression, and, therefore, CPT may influence the tumor-cell biology by up-regulating the uPA/plasmin system.</p>
Keywords CPT SN38 uPA RC-K8 H69
Amo Type Article
Published Date 2002-10
Publication Title Acta Medica Okayama
Volume volume56
Issue issue5
Publisher Okayama University Medical School
Start Page 223
End Page 227
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 12530505
Web of Science KeyUT 000178668100002
JaLCDOI 10.18926/AMO/40503
FullText URL 64_5_285.pdf
Author Nishimori, Hisakazu| Takahashi, Shunji| Kiura, Katsuyuki| Ennishi, Daisuke| Kobayashi, Takayuki| Sano, Koji| Shinozaki, Eiji| Yokoyama, Masahiro| Mishima, Yuko| Terui, Yasuhito| Chin, Keisho| Mizunuma, Nobuyuki| Ito, Yoshinori| Nishimura, Seiichiro| Takeuchi, Kengo| Ishikawa, Yuichi| Oguchi, Masahiko| Tanimoto, Mitsune| Hatake, Kiyohiko|
Abstract We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.
Keywords cancer of unknown primary site (CUP) cisplatin docetaxel prognosis
Amo Type Original Article
Published Date 2010-10
Publication Title Acta Medica Okayama
Volume volume64
Issue issue5
Publisher Okayama University Medical School
Start Page 285
End Page 291
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2010 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 20975761
Web of Science KeyUT 000283563300003
JaLCDOI 10.18926/AMO/49251
FullText URL 67_1_1.pdf
Author Nishimori, Hisakazu| Maeda, Yoshinobu| Tanimoto, Mitsune|
Abstract Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Chronic GVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases. Standard treatment is 1-2mg/kg/day of prednisone or an equivalent dose of methylprednisolone, with continued administration of a calcineurin inhibitor for steroid sparing. However, the prognosis of steroid-refractory chronic GVHD remains poor. Classically, chronic GVHD was said to involve predominantly Th2 responses. We are now faced with a more complex picture, involving possible roles for thymic dysfunction, transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF), B cells and autoantibodies, and Th1/Th2/Th17 cytokines, as well as regulatory T cells (Tregs), in chronic GVHD. More detailed research on the pathophysiology of chronic GVHD may facilitate the establishment of novel strategies for its prevention and treatment.
Keywords chronic GVHD Th17 Am80 regulatory T cell (Treg) steroid-refractory
Amo Type Review
Published Date 2013-02
Publication Title Acta Medica Okayama
Volume volume67
Issue issue1
Publisher Okayama University Medical School
Start Page 1
End Page 8
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2013 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 23439503
Web of Science KeyUT 000316829900001
JaLCDOI 10.18926/AMO/46635
FullText URL 65_3_215.pdf
Author Waseda, Koichi| Tanimoto, Yasushi| Hasegawa, Kenjiro| Miyahara, Nobuaki| Nojima, Daisuke| Ikeda, Genyo| Kanehiro, Arihiko| Okada, Chiharu| Kimata, Yoshihiro| Tanimoto, Mitsune|
Abstract Churg-Strauss syndrome (CSS) is a granulomatous necrotizing vasculitis of unknown etiology associated with bronchial asthma. Despite affecting small to medium-sized vessels, necrosis of the digits due to vasculitis is extremely rare. We report a case of CSS with necrosis of the toe tips. A 37-year-old woman with asthma, who had been diagnosed with CSS 2 years ago, was admitted to our hospital with an exacerbation of CSS. The patient had a high grade fever and complained of abdominal pain and numbness of the lower extremities. Blood examination revealed marked eosinophilia. The fever pattern, abdominal pain and blood eosinophilia showed improvement by combination treatment with prednisolone and cyclophosphamide. However, the color of her right toe tips changed, and necrosis finally resulted despite antithrombotic therapy. Arteriography showed narrowing of the dorsalis pedis artery and of the more peripheral arteries of her right leg. Stump plasty with negative pressure dressing therapy for the toe tips, but not amputation, was done to preserve the leg function. While numbness of the extremities remained, no recurrence of necrosis was seen. Clinicians need to be aware that rare complications of CSS, including necrosis of the digits, can occur.
Keywords bronchial asthma Churg-Strauss syndrome eosinophilia necrosis of toe tips stump plasty
Amo Type Case Report
Published Date 2011-06
Publication Title Acta Medica Okayama
Volume volume65
Issue issue3
Publisher Okayama University Medical School
Start Page 215
End Page 218
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2011 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 21709721
Web of Science KeyUT 000292017500010
JaLCDOI 10.18926/AMO/31714
FullText URL fulltext.pdf
Author Kawada, Kazuhiko| Yonei, Toshiro| Ueoka, Hiroshi| Kiura, Katsuyuki| Tabata, Masahiro| Takigawa, Nagio| Harada, Mine| Tanimoto, Mitsune|
Abstract <p>When the development of chemotherapeutic agents reaches the clinical trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5 human lung cancer cell lines. The correlation coefficient between the results of the HTCA and the MTT assay was 0.673, indicating a relatively good correlation. The correlation was most prominent in platinum analogues (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611). However, no significant correlation was observed in vinca alkaloids, etoposide, irinotecan, SN-38 (an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines to platinum analogues, and anthracyclines/anthracenedione. These results suggest that the MTT assay may be more convenient and quickly performed than the HTCA and can replace HTCA in evaluating the effects of anticancer agents, especially the platinum analogues and anthracyclines/anthracenedione.</p>
Keywords chemosensitivity test 3-(4 5-dimethylthiazol-2-yl)-2 5-diphenyltertrazolium bromide (MTT) assay clonogenic assay
Amo Type Article
Published Date 2002-06
Publication Title Acta Medica Okayama
Volume volume56
Issue issue3
Publisher Okayama University Medical School
Start Page 129
End Page 134
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 12108583
Web of Science KeyUT 000176521200002
JaLCDOI 10.18926/AMO/31705
FullText URL fulltext.pdf
Author Takata, Ichiro| Ueoka, Hiroshi| Kiura, Katsuyuki| Tabata, Masahiro| Takigawa, Nagio| Katayama, Hideki| Takemoto, Mitsuhiro| Hiraki, Yoshio| Harada, Mine| Tanimoto, Mitsune|
Abstract <p>A pilot study was conducted to assess the efficacy and feasibility of daily low-dose cisplatin with concurrent thoracic irradiation for clinically unresectable non-small-cell lung cancer (NSCLC). Patients with inoperable NSCLC who had poor risk factors such as advanced age, poor performance status, poor lung function, or concomitant active malignancy were entered into the study. Low-dose cisplatin (6 mg/m2) was administered daily before concurrent thoracic irradiation (2 Gy/day; total dose of 60 Gy) was given. Twenty-five patients were registered. The majority of the patients had either stage IIIA (24.0%) or stage IIIB (60.0%) disease. Fifteen patients (60.0%) completed the planned treatment. Both chemotherapy and radiotherapy were stopped in 3 patients (12.0%) due to poor response, and 7 patients (28.0%) partly received radiotherapy alone as a result of their toxicity response. The proportion of total administered dose to planned dose was 90.9% for chemotherapy and 99.3% for radiotherapy, which were comparable to those in previous studies for LA-NSCLC patients without poor risk factors. Grade 3 leukopenia and neutropenia developed in 14 patients (56.0%) and 10 patients (40.0%), respectively, but grade 4 toxicity was not encountered. Grade 3 pneumonitis and esophagitis were observed in 4 patients (16.0%) and 2 patients (8.0%), respectively. The overall response rate was 60.0%. The median survival time was 22 months, and the 2-year survival rate was 50.3%. Daily low-dose cisplatin and concurrent thoracic irradiation were well tolerated even by poor-risk patients with NSCLC, and showed a therapeutic efficacy similar to that for good-risk patients.</p>
Keywords non-small-cell lung cancer concurrent chemoradiotherapy low-dose cisplatin poor-risk factor
Amo Type Article
Published Date 2002-10
Publication Title Acta Medica Okayama
Volume volume56
Issue issue5
Publisher Okayama University Medical School
Start Page 261
End Page 266
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 12530510
Web of Science KeyUT 000178668100007
Author Hayashi, Eiko| Takata, Katsuyoshi| Sato, Yasuharu| Tashiro, Yukie| Tachiyama, Yoshiro| Sawada-Kitamura, Seiko| Hiramatsu, Yasushi| Sugiguchi, Shun| Nose, Soichiro| Hirokawa, Mitsuyoshi| Ando, Midori| Abd Mader, Lamia| Maeda, Yoshinobu| Tanimoto, Mitsune| Yoshino, Tadashi|
Published Date 2013-09
Publication Title Human Pathology
Volume volume44
Issue issue9
Content Type Journal Article
Author Ebinuma, Takayuki| Soga, Yoshihiko| Sato, Takamaro| Matsunaga, Kazuyuki| Kudo, Chieko| Maeda, Hiroshi| Maeda, Yoshinobu| Tanimoto, Mitsune| Takashiba, Shogo|
Published Date 2014-06
Publication Title Supportive Care in Cancer
Volume volume22
Issue issue6
Content Type Journal Article
Author Rai, Kammei| Takigawa, Nagio| Ito, Sachio| Kashihara, Hiromi| Ichihara, Eiki| Yasuda, Tatsuji| Shimizu, Kenji| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2012-12-03
Publication Title 岡山医学会雑誌
Volume volume124
Issue issue3
Content Type Journal Article
Author Murakami, Toshi| Takigawa, Nagio| Ninomiya, Takashi| Ochi, Nobuaki| Yasugi, Masaaki| Honda, Yoshihiro| Kubo, Toshio| Ichihara, Eiki| Hotta, Katsuyuki| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2014-01
Publication Title Lung Cancer
Volume volume83
Issue issue1
Content Type Journal Article
JaLCDOI 10.18926/AMO/48687
FullText URL 66_4_329.pdf
Author Matsushita, Koki| Mizushima, Takaaki| Shirahige, Akinori| Tanioka, Hiroaki| Sawa, Kiminari| Ochi, Koji| Tanimoto, Mitsune| Koide, Norio|
Abstract The relationship between pancreatic fibrosis and apoptosis of pancreatic acinar cells has not been fully elucidated. We reported that taurine had an anti-fibrotic effect in a dibutyltin dichloride (DBTC)-chronic pancreatitis model. However, the effect of taurine on apoptosis of pancreatic acinar cells is still unclear. Therefore, we examined apoptosis in DBTC-chronic pancreatitis and in the AR42J pancreatic acinar cell line with/without taurine. Pancreatic fibrosis was induced by a single administration of DBTC. Rats were fed a taurine-containing diet or a normal diet and were sacrificed at day 5. The AR42J pancreatic acinar cell line was incubated with/without DBTC with taurine chloramines. Apoptosis was determined by using terminal deoxynucleotidyl transferase-mediated dUTP-digoxigenin nick end labeling (TUNEL) assay. The expression of Bad and Bcl-2 proteins in the AR42J cells lysates was detected by Western blot analysis. The apoptotic index of pancreatic acinar cells in DBTC-administered rats was significantly increased. Taurine treatment inhibited pancreatic fibrosis and apoptosis of acinar cells induced by DBTC. The number of TUNEL-positive cells in the AR42J pancreatic acinar cell lines was significantly increased by the addition of DBTC. Incubation with taurine chloramines ameliorated these changes. In conclusion, taurine inhibits apoptosis of pancreatic acinar cells and pancreatitis in experimental chronic pancreatitis.
Keywords apoptosis chronic pancreatitis pancreatic acinar cells taurine
Amo Type Original Article
Published Date 2012-08
Publication Title Acta Medica Okayama
Volume volume66
Issue issue4
Publisher Okayama University Medical School
Start Page 329
End Page 334
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2012 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 22918205
Web of Science KeyUT 000307918900005
Related Url http://ousar.lib.okayama-u.ac.jp/metadata/49739
JaLCDOI 10.18926/AMO/54499
FullText URL 70_4_243.pdf
Author Osawa, Masahiro| Ohashi, Kadoaki| Kubo, Toshio| Ichihara, Eiki| Takata, Saburo| Takigawa, Nagio| Takata , Minoru| Tanimoto, Mitsune| Kiura, Katsuyuki|
Abstract Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p<0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation.
Keywords vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse
Amo Type Original Article
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 243
End Page 253
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549668
Web of Science KeyUT 000384748600003
JaLCDOI 10.18926/14839
Title Alternative 脂質代謝に関連した気管支喘息患者における白血球ロイコトリエン産生能に対するα-リノレン酸食の効果
FullText URL 72_045_054.pdf
Author Okamoto, Makoto| Mitsunobu, Fumihiro| Ashida, Kozo| Hosaki, Yasuhiro| Tsugeno, Hirofumi| Nishida, Norikazu| Yokoi, Tadashi| Takata, Shingo| Tanizaki, Yoshiro| Tanimoto, Mitsune|
Abstract Dietary sources of a -linolenic acid, such as perilla seed oil, may have the capacity to inhibit the generation of leukotrienes (LTs) by leucocytes in patients with asthma, as has been reported with the consumption of other long - chain n- 3 fatty a-cids. The factors affecting the suppression of leukotriene (LT) C4 generation by leucocytes were examined by comparing the clinical features of patients with asthma who had been given dietary perilla seed oil (n - 3 fatty acids). Group A consisted of patients in whom the leucocyte generation of dietary perilla seed oil LTC4 was suppressed by this procedure. Group B consisted of those in whom LTC4 generation was not suppressed. LTC4 generation by leucocytes significantly decreased in group A for two (P<0.05) and four weeks (P<O. OS), conversely, significantly increased in group B for four weeks (p<O. OS). The two study groups differed significantly in LTC4 generation by leucocytes after four weeks of dietary supplementation (P<0.05). Ventilatory parameters such as peak expiratory flow (PEF) , forced vital capacity (FVC) and forced expiratory volume in one second (FEV(1.O)) increased significantly after four weeks of dietary supplementation in group A (P<0.05). Values of PEF, FVC, FEV(1.O) and V(25) between groups A and B significantly differed prior to dietary supplementation. Serum levels of total cholesterol, LDL- cholesterol and phospholipid were significantly decreased by dietary supplementation in group A after four weeks. Serum levels of total-choles terol, triglyceride, HDL-Cholesterol, LDL-Cholesterol and phospholipid values between the two study groups differed significantly prior to dietary supplementation. Serum levels of triglyceride and LDL- cholesterol differed significantly between the two study groups after four weeks of dietary supplementation. The effects of dietary supplementation with perilla seed oil to patients with asthma by suppressing the generation of LTC4 is associated with clinical features such as respiratory function and lipometabolism.
Abstract Alternative エゴマ油のようなα-リノレン酸食が他のn-3系不飽和脂肪酸食において報告されてきた様に喘息患者の白血球ロイコトリエン(LTs)産生能を抑制すると考えられる。そこでエゴマ油(n-3系脂肪酸)を摂取した気管支喘息患者の臨床所見を比較することによって白血球ロイコトリエン(LT)C4の抑制に影響する因子を検討した。A群はエゴマ油摂取により白血球LTC4の産生能が抑制された群であり、B群は白血球LTC4の産生能が抑制されなかった群である。A群では食事摂取2週後(P<0.05),4週後(P<0.05)に白血球LTC4産生能が低下した。逆にB群では摂取4週後有意に増加した(P<0.05)0 2群間で食事摂取4遡後に白血球LTC4産生能に有意差がみられた(P<0.05)。ピークフロー値(PEF)、努力性肺活量(FVC)、1秒量(FEV(1))といった呼吸機能はA群において食事摂取4週後に有意に上昇した(P<0.05)。食事摂取前のPEF、FVC、FEV(1)、V(25)はA群,B群の2群間で有意差がみられた。A群において血清総コレステロール、低比重リポ蛋白(LDL)コレステロール、リン脂質は食事摂取4週後に有意に低下した。食事摂取前の血清総コレステロール、中性脂肪、高比重リポ蛋白コレステロール、LDLコレステロール、リン脂質において2群間に有意差がみられた。血清中性脂肪、LDLコレステロールは食事摂取4週後2群間に有意差がみられた。気管支喘息患者のある群へのエゴマ油食はLTC4産生能を抑制し、それには呼吸機能や脂質代謝といった臨床因子が関連していると考えられた。
Keywords alpha -linolenic acid leukotrieneC4 bronchial asthma lipometabolism
Publication Title 岡大三朝分院研究報告
Published Date 2002-02-01
Volume volume72
Start Page 45
End Page 54
ISSN 0918-7839
language 英語
File Version publisher
NAID 120002308212